I met with Dr. Thomas Maddox, the director of the Health Systems Innovation Lab at BJC/WashU, to discuss an upcoming pilot program to remotely monitor patients with heart failure. The lab has partnered with Myia Labs using technology they have developed to monitor these patients at home. We discuss the ‘ballistocardiograph’ and how they are planning to incorporate it into clinical practice.
In 2002, NEJM published the AFFIRM trial, showing no difference in outcomes between patients with atrial fibrillation treated with rate or rhythm control strategy. But does that mean rate control should be the default treatment method? In this episode I discuss this topic with Dr. Mitch Faddis and Dr. Philip Cuculich and their approach to this decision.
I met with Dr. Alan Braverman to talk about aortic diseases (aka aortopathies) such as Marfan’s disease, Ehlers-Danlos and Loeys-Dietz. We discuss everything from clinical presentations and genetics to treatments.
Articles referenced: NEJM Atenolol vs Losartan in Marfan’s